PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:32 AM ET

Sponsor Check › Person

JS
No photo found yet (own website and image search run after this page is viewed)

Jon S. Saxe

Named as an officer, director or promoter on SEC Form D filings · CA, TX · Mar 7, 2012 → Dec 20, 2024

6deals (issuers)
$89.5Mreported sold
193investors
23Form D filings
2012–2024years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:16 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Jon S. Saxe is listed as an executive officer and director on 23 SEC Form D filings by 6 issuers between Nov 2009 and Nov 2025. Largest by amount reported sold: Lumos Pharma, Inc. (Austin, TX — pharmaceuticals — 2014–2016; $34M reported sold to 6 investors), Armetheon, Inc. (Menlo Park, CA — biotechnology — 2014–2015; $24.4M reported sold to 32 investors), EPALEX Corp (Mountain View, CA — pharmaceuticals — 2018–2025; $20.3M reported sold to 15 investors), VistaGen Therapeutics, Inc. (South San Francisco, CA — pharmaceuticals — 2012–2023; $4.78M reported sold to 129 investors), Aether Therapeutics Inc. (Austin, TX — biotechnology — 2024; $4.08M reported sold to 1 investors) and 1 more (all listed below).

What this means A repeat sponsor — 6 separate companies raised money with this person listed as executive officer and director, over about 16 years. Across those companies the filings report $89.5M sold in total.

Listed alongside Jerrold D. Dotson (8 shared filings), Shawn K. Singh (8 shared filings), H. Ralph Snodgrass (7 shared filings), Brian J. Underdown (6 shared filings), Michael Rogawski (6 shared filings) and 49 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jon. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — none found.

What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.

We compared 23 public filings for Jon S. Saxe and found 23 differences, 2 worth asking the sponsor about: Paid seller listed without a CRD number: Issuer Direct Sales Only; 10 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Jon S. Saxe has not run yet — it is joining a line of 56,173 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:16 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Jon S. Saxe..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:16 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

23 differences found between the filings for Jon S. Saxe — 2 worth asking about (compared 23 filings on Oct 24, 2026)

Note · Sep 17, 1992 – Nov 16, 1995

Bankruptcy case: James W. Eisenberg Medical Corp v. Rotunno — filed Sep 17, 1992

United States Bankruptcy Court, C.D. California docket "James W. Eisenberg Medical Corp v. Rotunno" filed Sep 17, 1992, closed Nov 16, 1995. Mary L. Rotunno (listed on the same filings) is listed as Defendant ("Rotunno"). Our match estimate: 65%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, C.D. California ↗Mary L. Rotunno — PartnerFacts page ↗
Sources
Note · Oct 14, 2022

15% of the money raised went to insiders — EPALEX Corp

The Oct 14, 2022 Form D reports $4,260,617 sold and $650,000 of the proceeds used for payments to officers, directors or promoters. Issuer's note: "Estimated total cash compensation in respect of fiscal year ending December 31, 2022.".

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Oct 14, 2022 ↗EPALEX Corp — PartnerFacts page ↗
Sources
Note · Feb 6, 2014

16% of the money raised went to insiders — Lumos Pharma, Inc.

The Feb 6, 2014 Form D reports $6,500,000 sold and $1,051,186 of the proceeds used for payments to officers, directors or promoters. Issuer's note: "This amount constitutes repayment of debt by the issuer to Mr. Hawkins and Mr. Saxe under promissory notes.".

What this means The filing reports how much of the money raised was paid to insiders. Over 10% is high for most deals. Ask what it paid for.

Form D · Feb 6, 2014 ↗Lumos Pharma, Inc. — PartnerFacts page ↗
Sources
Note · Feb 21, 2023

Jon S. Saxe appears on 1 deal that stopped filing before reaching its target

VistaGen Therapeutics, Inc. (last filing Feb 21, 2023; $4,778,750 sold of $10,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

VistaGen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jan 19, 2024

Paid seller listed without a CRD number: Issuer Direct Sales Only — Aether Therapeutics Inc.

Issuer Direct Sales Only is listed as receiving sales compensation on 1 filing (Jan 19, 2024) with no FINRA CRD number given.

What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.

Form D · Jan 19, 2024 ↗BrokerCheck search: Issuer Direct Sales Only ↗Aether Therapeutics Inc. — PartnerFacts page ↗
Sources
Worth asking · Sep 30, 2009 – Feb 21, 2023

10 Form Ds were filed more than 15 days after the first sale

Form D filed 445 days after the first sale — EPALEX Corp · Form D filed 85 days after the first sale — VistaGen Therapeutics, Inc. · Form D filed 145 days after the first sale — VistaGen Therapeutics, Inc. · Form D filed 72 days after the first sale — VistaGen Therapeutics, Inc. · Form D filed 108 days after the first sale — VistaGen Therapeutics, Inc. · and 5 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Nov 20, 2018 ↗EPALEX Corp — PartnerFacts page ↗Form D · Sep 21, 2018 ↗VistaGen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Apr 27, 2010 – Dec 20, 2024

12 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — EPALEX Corp (latest filing Dec 20, 2024) · No amendment in the last 12 months on an offering that may still be open — Aether Therapeutics Inc. (latest filing Jan 19, 2024) · No amendment in the last 12 months on an offering that may still be open — VistaGen Therapeutics, Inc. (latest filing Feb 21, 2023) · No amendment in the last 12 months on an offering that may still be open — EPALEX Corp (latest filing Oct 14, 2022) · No amendment in the last 12 months on an offering that may still be open — EPALEX Corp (latest filing Nov 20, 2018) · and 7 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Dec 20, 2024 ↗EPALEX Corp — PartnerFacts page ↗Form D · Jan 19, 2024 ↗Aether Therapeutics Inc. — PartnerFacts page ↗
Sources
Note · Feb 6, 2014 – May 1, 2015

Jon S. Saxe's role changed at Lumos Pharma, Inc.: executive officer, director → director

The Feb 6, 2014 filing lists Jon S. Saxe as executive officer, director; the May 1, 2015 Form D/A lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Feb 6, 2014 ↗Form D/A · May 1, 2015 ↗Jon S. Saxe — PartnerFacts page ↗Lumos Pharma, Inc. — PartnerFacts page ↗
Sources
Note · Jan 10, 2019 – Dec 18, 2020

Offering amount changed between filings — EPALEX Corp

The Jan 10, 2019 filing says $20,000,000 offered; the Dec 18, 2020 Form D/A says $20,296,275.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Jan 10, 2019 ↗Form D/A (later) · Dec 18, 2020 ↗EPALEX Corp — PartnerFacts page ↗
Sources
Note · Feb 6, 2014 – May 1, 2015

Offering amount changed between filings — Lumos Pharma, Inc.

The Feb 6, 2014 filing says $7,500,000 offered; the May 1, 2015 Form D/A says $13,000,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Feb 6, 2014 ↗Form D/A (later) · May 1, 2015 ↗Lumos Pharma, Inc. — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Mar 11, 2010

Offering amount changed between filings — AVC Royalty Fund I, LLC

The Nov 2, 2009 filing says $1,440,000 offered; the Mar 11, 2010 Form D says $2,024,100.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Form D (earlier) · Nov 2, 2009 ↗Form D (later) · Mar 11, 2010 ↗AVC Royalty Fund I, LLC — PartnerFacts page ↗
Sources
Note · Jan 10, 2019 – Dec 18, 2020

Minimum investment changed between filings — EPALEX Corp

The Jan 10, 2019 filing lists a minimum of $25,000; the Dec 18, 2020 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Jan 10, 2019 ↗Form D/A (later) · Dec 18, 2020 ↗EPALEX Corp — PartnerFacts page ↗
Sources
Note · Feb 6, 2014 – May 1, 2015

Minimum investment changed between filings — Lumos Pharma, Inc.

The Feb 6, 2014 filing lists a minimum of $45,000; the May 1, 2015 Form D/A lists $0.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Feb 6, 2014 ↗Form D/A (later) · May 1, 2015 ↗Lumos Pharma, Inc. — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Mar 7, 2012

Jon S. Saxe is written 2 different ways on the filings

listed as "Jon Saxe" on 6 filings (from Nov 2, 2009), and "Jon S. Saxe" on 17 filings (from Mar 7, 2012).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Nov 2, 2009 ↗Form D · Mar 7, 2012 ↗Jon S. Saxe — PartnerFacts page ↗
Sources
Note · Mar 7, 2012 – Jan 31, 2020

Industry group changed between filings — VistaGen Therapeutics, Inc.

"Biotechnology" (Mar 7, 2012 to Dec 12, 2019); then "Pharmaceuticals" (Jan 31, 2020 to Feb 21, 2023).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Mar 7, 2012 ↗Form D · Jan 31, 2020 ↗VistaGen Therapeutics, Inc. — PartnerFacts page ↗
Sources
Note · Aug 29, 2014 – Mar 11, 2015

Industry group changed between filings — Armetheon, Inc.

"Other" (Aug 29, 2014); then "Biotechnology" (Mar 11, 2015).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Aug 29, 2014 ↗Form D · Mar 11, 2015 ↗Armetheon, Inc. — PartnerFacts page ↗
Sources
Note · Mar 7, 2012 – Aug 22, 2017

Reported revenue range changed between filings — VistaGen Therapeutics, Inc.

"$1,000,001 - $5,000,000" (Mar 7, 2012); then "$1 - $1,000,000" (Jun 30, 2014); then "No Revenues" (Aug 6, 2015); then "Decline to Disclose" (Aug 22, 2017).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Mar 7, 2012 ↗Form D · Jun 30, 2014 ↗Form D · Aug 6, 2015 ↗Form D · Aug 22, 2017 ↗
Sources
Note · Feb 6, 2014 – Apr 18, 2016

Reported revenue range changed between filings — Lumos Pharma, Inc.

"No Revenues" (Feb 6, 2014); then "Decline to Disclose" (Apr 18, 2016).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Feb 6, 2014 ↗Form D · Apr 18, 2016 ↗Lumos Pharma, Inc. — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Mar 11, 2010

Reported revenue range changed between filings — AVC Royalty Fund I, LLC

"No Revenues" (Nov 2, 2009); then "Decline to Disclose" (Mar 11, 2010).

What this means This is the size band the issuer picks for itself on the form. A change can mean the business grew or shrank — or that it chose not to say. Ask for current numbers.

Form D · Nov 2, 2009 ↗Form D · Mar 11, 2010 ↗AVC Royalty Fund I, LLC — PartnerFacts page ↗
Sources
Note · Jan 14, 2016 – Nov 22, 2024

Same name, different state: "Jon Saxe" (AZ) is a separate record

This page covers filings where the address state is CA or TX. A separate record, "Jon Saxe" with address state AZ, is listed on 6 filings — most recently by NuvOx Therapeutics, Inc. (Nov 22, 2024). Both records have filings in the same period (Jan 14, 2016 to Nov 22, 2024).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Jon Saxe (AZ) — PartnerFacts page ↗Form D · Nov 22, 2024 ↗NuvOx Therapeutics, Inc. — PartnerFacts page ↗Jon S. Saxe (CA,TX) — this page ↗
Sources
Note · Jan 10, 2019 – Dec 18, 2020

Address moved from Pleasanton, CA to Mountain View, CA — EPALEX Corp

The people listed on the Jan 10, 2019 filing give Pleasanton, CA; on the Dec 18, 2020 filing they give Mountain View, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jan 10, 2019 ↗Form D/A · Dec 18, 2020 ↗EPALEX Corp — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Mar 11, 2010

Address moved from Sunnyvale, CA to Fremont, CA — AVC Royalty Fund I, LLC

The people listed on the Nov 2, 2009 filing give Sunnyvale, CA; on the Mar 11, 2010 filing they give Fremont, CA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Nov 2, 2009 ↗Form D · Mar 11, 2010 ↗AVC Royalty Fund I, LLC — PartnerFacts page ↗
Sources
Note · Nov 2, 2009 – Nov 10, 2025

Jon S. Saxe is listed with 2 different address states: CA, TX

CA on 20 filings (Nov 2, 2009 to Nov 10, 2025); TX on 3 filings (May 1, 2015 to Jan 19, 2024).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Nov 2, 2009 ↗Form D/A · May 1, 2015 ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

2 of 20 offerings report sales commissions totalling $1,399,000; 0 report finder's fees; 2 report proceeds to related persons totalling $800,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Nov 10, 2025 D
EPALEX Corp
File 021-563583
$0$0$0
The proceeds are available to fund general working capital requirements; as of the date of this filing, no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of finders fees or other compensation.
None listed on this filingEDGAR ↗
Dec 20, 2024 D
EPALEX Corp
File 021-532895
$0$0$0
The proceeds are available to fund general working capital requirements; as of the date of this filing, no detailed operating budget has been adopted; and no proceeds have been or are proposed to be used for payments of finders fees or other compensation.
None listed on this filingEDGAR ↗
Jan 19, 2024 D
Aether Therapeutics Inc.
File 021-502978
$0$0$150,000 (est.)
$150,000-$200,000 compensation paid to Chief Executive Officer.
Issuer Direct Sales Only no CRD number reportedEDGAR ↗
Feb 21, 2023 D
VistaGen Therapeutics, Inc.
File 021-473834
$0$0$0None listed on this filingEDGAR ↗
Oct 14, 2022 D
EPALEX Corp
File 021-461755
$0$0$650,000
Estimated total cash compensation in respect of fiscal year ending December 31, 2022.
None listed on this filingEDGAR ↗
Dec 18, 2020 D/A
EPALEX Corp
File 021-330183
$0$0$0None listed on this filingEDGAR ↗
Jan 31, 2020 D
VistaGen Therapeutics, Inc.
File 021-359548
$0$0$0None listed on this filingEDGAR ↗
Dec 12, 2019 D
VistaGen Therapeutics, Inc.
File 021-355353
$0$0$0None listed on this filingEDGAR ↗
Nov 20, 2018 D
EPALEX Corp
File 021-326150
$0$0$0None listed on this filingEDGAR ↗
Sep 21, 2018 D
VistaGen Therapeutics, Inc.
File 021-321921
$0$0$0None listed on this filingEDGAR ↗
Aug 22, 2017 D
VistaGen Therapeutics, Inc.
File 021-293292
$0$0$0None listed on this filingEDGAR ↗
Apr 18, 2016 D
Lumos Pharma, Inc.
File 021-261574
$0$0$0
All proceeds are for working capital.
None listed on this filingEDGAR ↗
Aug 6, 2015 D
VistaGen Therapeutics, Inc.
File 021-245256
$0$0$0None listed on this filingEDGAR ↗
May 1, 2015 D/A
Lumos Pharma, Inc.
File 021-211391
$0$0$0
All proceeds are for working capital.
None listed on this filingEDGAR ↗
Mar 11, 2015 D
Armetheon, Inc.
File 021-235599
$1,378,000 (est.)$0$0Locust Walk Securities LLC BrokerCheck CRD 156174 ↗EDGAR ↗
Aug 29, 2014 D
Armetheon, Inc.
File 021-223872
$0$0$0None listed on this filingEDGAR ↗
Jun 30, 2014 D
VistaGen Therapeutics, Inc.
File 021-220091
$0$0$0None listed on this filingEDGAR ↗
Mar 7, 2012 D
VistaGen Therapeutics, Inc.
File 021-174463
$21,000$0$0Noble Financial Capital Markets BrokerCheck CRD 15768 ↗EDGAR ↗
Jun 2, 2010 D
AVC Royalty Fund I, LLC
File 021-142874
$0$0$0None listed on this filingEDGAR ↗
Mar 11, 2010 D
AVC Royalty Fund I, LLC
File 021-135770
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 6

Every issuer that named Jon S. Saxe on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

EC
Pharmaceuticals

EPALEX Corp

Mountain View, CA · Nov 20, 2018 → Nov 10, 2025 · 6 filings
  • Nov 10, 2025 · D · $1,200,000 sold of $3,199,991 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 20, 2024 · D · $3,999,999 sold of $14,999,998 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 14, 2022 · D · $4,260,617 sold of $8,499,980 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 18, 2020 · D/A · $20,296,275 sold of $20,296,275 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 10, 2019 · D · $9,998,370 sold of $20,000,000 · 1 investors · min. $25,000 · role: Director EDGAR ↗
  • Nov 20, 2018 · D · $999,284 sold of $1,000,000 · 5 investors · min. $25,000 · role: Director EDGAR ↗

Raised $20.3M from 15 investors (100% of the $3.2M target) as of the latest filing. Jon is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Logo
Biotechnology

Aether Therapeutics Inc.

Austin, TX · Jan 19, 2024
  • Jan 19, 2024 · D · $4,078,010 sold of $6,580,866 · 1 investors · min. $50,000 · role: Executive Officer, Director EDGAR ↗

Raised $4.08M from 1 investor (62% of the $6.58M target) as of the latest filing. Jon is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VT
Pharmaceuticals

VistaGen Therapeutics, Inc.

South San Francisco, CA · Mar 7, 2012 → Feb 21, 2023 · 8 filings
  • Feb 21, 2023 · D · $0 sold of $2,798,415 · 129 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 31, 2020 · D · $2,750,000 sold of $2,750,000 · 3 investors · min. $250,000 · role: Director EDGAR ↗
  • Dec 12, 2019 · D · $650,000 sold of $650,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 21, 2018 · D · $4,778,750 sold of $5,750,000 · 33 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 22, 2017 · D · $1,037,750 sold of $1,037,750 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 6, 2015 · D · $1,930,281 sold of $10,000,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 30, 2014 · D · $1,570,000 sold of $3,000,000 · 21 investors · min. $5,000 · role: Director EDGAR ↗
  • Mar 7, 2012 · D · $500,000 sold of $3,000,000 · 6 investors · min. $25,000 · role: Director EDGAR ↗

Raised $4.78M from 129 investors (100% of the $2.8M target) as of the latest filing. Jon is listed as director on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LP
Pharmaceuticals

Lumos Pharma, Inc.

Austin, TX · Feb 6, 2014 → Apr 18, 2016 · 3 filings
  • Apr 18, 2016 · D · $33,999,991 sold of $33,999,991 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 1, 2015 · D/A · $13,000,000 sold of $13,000,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 6, 2014 · D · $6,500,000 sold of $7,500,000 · 3 investors · min. $45,000 · role: Executive Officer, Director EDGAR ↗

Raised $34M from 6 investors (100% of the $34M target) as of the latest filing. Jon is listed as director, executive officer on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

A
Biotechnology

Armetheon, Inc.

Menlo Park, CA · Aug 29, 2014 → Mar 11, 2015 · 2 filings
  • Mar 11, 2015 · D · $24,351,006 sold of $35,000,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 29, 2014 · D · $6,999,998 sold of $7,000,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $24.4M from 32 investors (70% of the $35M target) as of the latest filing. Jon is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AR
Other

AVC Royalty Fund I, LLC

Fremont, CA · Nov 2, 2009 → Jun 2, 2010 · 3 filings
  • Jun 2, 2010 · D · $50,000 sold of $2,000,000 · 1 investors · min. $20,000 · role: Director (Director of Managing Member) EDGAR ↗
  • Mar 11, 2010 · D · $2,024,100 sold of $2,024,100 · 10 investors · min. $20,000 · role: Director EDGAR ↗
  • Nov 2, 2009 · D · $1,440,000 sold of $1,440,000 · 5 investors · min. $20,000 · role: Director (Director of Managing Member) EDGAR ↗

Raised $2.02M from 10 investors (100% of the $2M target) as of the latest filing. Jon is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (1)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Jon Saxe — AZ, 2 issuers, Jan 14, 2016 → Nov 22, 2024 · no shared issuer

People around Jon 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

AV
Management entity

Arbor Vita Corporation

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

SS
No photo found yet (own website and image search run after this page is viewed)
Person

Shawn K. Singh

Executive Officer, Director · 8 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

JD
No photo found yet (own website and image search run after this page is viewed)
Person

Jerrold D. Dotson

Executive Officer · 8 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

HS
No photo found yet (own website and image search run after this page is viewed)
Person

H. Ralph Snodgrass

Executive Officer, Director · 7 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

RM
No photo found yet (own website and image search run after this page is viewed)
Person

Randall Murphy

Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

MR
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Rogawski

Director · 6 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

BU
No photo found yet (own website and image search run after this page is viewed)
Person

Brian J. Underdown

Director · 6 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

JG
No photo found yet (own website and image search run after this page is viewed)
Person

Jerry B. Gin

Director · 5 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

BM
No photo found yet (own website and image search run after this page is viewed)
Person

Brendan Magrab

Executive Officer, Director · 4 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Mark A. Smith

Executive Officer · 4 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

MS
No photo found yet (own website and image search run after this page is viewed)
Person

Matthew Smith

Director · 4 shared filings (1 issuer) · also on 3 other issuers

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Richard John Hawkins

Executive Officer, Director, Promoter · 3 shared filings (1 issuer) · also on 6 other issuers

Richard John Hawkins is on 7 issuers in total — a repeat sponsor. Their page lists every one.

JL
No photo found yet (own website and image search run after this page is viewed)
Person

Joseph Lu

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

PL
No photo found yet (own website and image search run after this page is viewed)
Person

Peter S. Lu

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Charles Trimble

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

FC
No photo found yet (own website and image search run after this page is viewed)
Person

Francis Cano

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

TR
No photo found yet (own website and image search run after this page is viewed)
Person

Thomas Recine

Director · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

MM
No photo found yet (own website and image search run after this page is viewed)
Person

Mark McPartland

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

WS
No photo found yet (own website and image search run after this page is viewed)
Person

William Smith

Director · 3 shared filings (1 issuer) · also on 6 other issuers

William Smith is on 7 issuers in total — a repeat sponsor. Their page lists every one.

EB
No photo found yet (own website and image search run after this page is viewed)
Person

Eugene Bauer

Director · 3 shared filings (1 issuer) · also on 10 other issuers

Eugene Bauer is on 11 issuers in total — a repeat sponsor. Their page lists every one.

PM
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Milner

Executive Officer, Director · 2 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

PD
No photo found yet (own website and image search run after this page is viewed)
Person

Pascal Druzgala

Executive Officer, Director · 2 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

GC
No photo found yet (own website and image search run after this page is viewed)
Person

George Gilbert Cloyd

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

RH
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Heft

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Ann K. Cunningham

Director · 2 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Lalande

Director · 2 shared filings (1 issuer) · also on 15 other issuers

Kevin Lalande is on 16 issuers in total — a repeat sponsor. Their page lists every one.

AR
No photo found yet (own website and image search run after this page is viewed)
Person

Arthur Franklin Rice

Executive Officer, Director · 2 shared filings (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

DC
No photo found yet (own website and image search run after this page is viewed)
Person

Didric Cedarholm

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

FR
No photo found yet (own website and image search run after this page is viewed)
Person

Franklin Rice

Executive Officer · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

GB
No photo found yet (own website and image search run after this page is viewed)
Person

Gregory A. Bonfiglio

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

EO
No photo found yet (own website and image search run after this page is viewed)
Person

Eric K. Olson

Director · 1 shared filing (1 issuer) · also on 1 other issuer

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

SJ
No photo found yet (own website and image search run after this page is viewed)
Person

Steven P. James

Director · 1 shared filing (1 issuer) · also on 4 other issuers

Steven P. James is on 5 issuers in total — a repeat sponsor. Their page lists every one.

MK
No photo found yet (own website and image search run after this page is viewed)
Person

Muralitharan Kengatharan

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

KM
No photo found yet (own website and image search run after this page is viewed)
Person

Kengatharan Muralitharan

Executive Officer, Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

UB
No photo found yet (own website and image search run after this page is viewed)
Person

Underdown J. Brian

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

MP
No photo found yet (own website and image search run after this page is viewed)
Person

Michele Park

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

GC
No photo found yet (own website and image search run after this page is viewed)
Person

G. Gilbert Cloyd

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

KL
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Lelande

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

CW
No photo found yet (own website and image search run after this page is viewed)
Person

Cameron Wheeler

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

TS
No photo found yet (own website and image search run after this page is viewed)
Person

Tracy Saxton

Director · 1 shared filing (1 issuer)

Listed on the same filings as Jon S. Saxe. Their page shows their other deals.

The team behind the deals

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); KY (Kentucky Secretary of State — Business Entity Search (sosbes.sos.ky.gov), searched by issuer name, data as of Oct 24, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 6 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

3 Regulation Crowdfunding filings — tap to see each filing
SourceFiledFormIssuerAmount offered (as reported)Amount sold (as reported)Matched on
EDGAR ↗Feb 21, 2025
File 020-34651
Regulation Crowdfunding progress update (Form C-U)
Progress update filed · deadline Dec 6, 2024
Aether THERAPEUTICS
Austin, TX
$10,002 target · $800,032 maximum
via NetCapital Funding Portal Inc. (CRD 283596 · FINRA funding portals ↗)
Not reported on this formsigner name on this filing (Jon Saxe) + listed as a related person on Form D filings of the same issuer (CIK 2004745) · 85%
EDGAR ↗Sep 6, 2024
File 020-34651
Regulation Crowdfunding offering — amendment (Form C/A)
Amendment filed · deadline Dec 6, 2024
Aether THERAPEUTICS
Austin, TX
$10,002 target · $800,032 maximum
via NetCapital Funding Portal Inc. (CRD 283596 · FINRA funding portals ↗)
Not reported on this formsigner name on this filing (Jon Saxe) + listed as a related person on Form D filings of the same issuer (CIK 2004745) · 85%
EDGAR ↗Aug 21, 2024
File 020-34651
Regulation Crowdfunding offering (Form C)
Offering filed · deadline Dec 6, 2024
Aether THERAPEUTICS
Austin, TX
$10,002 target · $800,032 maximum
via NetCapital Funding Portal Inc. (CRD 283596 · FINRA funding portals ↗)
Not reported on this formsigner name on this filing (Jon Saxe) + listed as a related person on Form D filings of the same issuer (CIK 2004745) · 85%

Amounts are as reported by the issuer on the form; Regulation Crowdfunding forms report a target and maximum, not sales. Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Jon S. Saxe by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 6 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Jon S. Saxe is listed on, as found in their SEC filings (Form C, Reg A, Form ADV, EDGAR profile) or on the sponsor's own site; none belongs to the person unless the sponsor's site says so. Checked Oct 24, 2026.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Menlo Park, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Found on the sponsor's own site

aethertherapeutics.com ↗ found on Aether Therapeutics Inc. (aethertherapeutics.com — Form C 0001669191-25-000390 (issuer website as filed))

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗Texas re:SearchTX court records ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗Texas Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Jon S. Saxe appears on a new Form D, or when a court case or SEC action is matched to them. See plans →